Artemisinin Combination Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Artemisinin Combination Therapy Market is segmented by Combination Therapy Type (Artemether-Lumefantrine, Artesunate-Amodiaquine, Artesunate-Pyronaridine, Artesunate-Sulfadoxine-Pyrimethamine and others) and Geography

Market Snapshot

Picture1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: Middle-East and Africa
CAGR: 8.31 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Artemisinin combination therapy (ACT) is used for the treatment of Plasmodium falciparum malaria. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and under-developing countries. 

According to the “World Malaria Report 2018” by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 related deaths in 2017 and most of the malaria cases were attributed to Plasmodium falciparum. Hence the high prevalence of malaria is driving the growth of this market. Other factors like an increase in awareness initiatives by governments and research for new anti-malarial drugs and therapies are also helping this market grow. However, side-effects of anti-malarial drugs and the presence of counterfeit and substandard drugs are restraining the growth of this market.

Scope of the Report

As per the scope of the report, artemisinin is a plant derivative isolated from Artemisia annua, or sweet wormwood, which is known to effectively and swiftly reduce the number of plasmodium parasites in the blood of malaria patients. The artemisinin-combination therapy (ACT) for the treatment of Plasmodium falciparum malaria.

By Combination Therapy Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Artesunate-Pyronaridine
Artesunate-Sulfadoxine-Pyrimethamine
Others
Geography
Asia-Pacific
India
Pakistan
Vietnam
Indonesia
Myanmar
Cambodia
Rest of Asia-Pacific
South America
Venezuela
Brazil
Colombia
Rest Of South America
Middle-East and Africa
GCC
South Africa
Nigeria
Uganda
Kenya
Zimbabwe
Niger
Cameroon
Ghana
Democratic Republic of the Congo
Rest of Middle East and Africa
Rest of the World

Report scope can be customized per your requirements. Click here.

Key Market Trends

Artemether-Lumefantrine Segment is Expected to Dominate the Market During the Forecast Period

Artemether-Lumefantrine is a combination of the two medications artemether and lumefantrine. It is used to treat malaria caused by Plasmodium falciparum that is not treatable with chloroquine. They were both developed in China. It is one of the drugs on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

The World Health Organization recommends that uncomplicated Plasmodium falciparum malaria should be treated with an artemisinin- lumefantrine combination therapy. Artemether-lumefantrine is the most widely used Artemisinin Combination Therapy (ACT), accounting for 73% of global ACT procurement according to an article by Frank Kloprogge et al published in PLoS Medicine Journal 2018, which makes it one of the most widely used anti-infective agents in the world today. As this combination is used as the first-line drug for malaria in most countries, it is expected to cover a large share in the global artemisinin combination therapy market.

Picture4.png

Middle East and Africa is Expected to Show a High Growth During the Forecast Period

The Middle East and Africa held the largest share in the artemisinin combination therapy market due to the presence of a large production base of artemisinin herbs and rising demand in malaria-endemic countries that are contributing to the growth of the market.

According to the World Health Organization (WHO), there were an estimated 219 million cases of malaria worldwide in 2017, out of which WHO African Region carried a disproportionately high share of the global malaria burden. In 2017, the region contributed 92% of malaria cases and 93% of malaria deaths. The WHO Eastern Mediterranean Region was home for nearly 2% of the global malaria cases. Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the artemisinin combination therapy market.

Picture9.png

Competitive Landscape

Majority of the Artemisinin Combination Therapy drugs are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Some of the global players are based in developed countries like United States, United Kingdom, France, Germany, and Japan.

However, due to the higher prevalence of malaria in developing regions like the Asia-Pacific and Africa, many companies are also establishing their production plants in these regions. Additionally, many new companies from these regions are also emerging.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Prevalence of Malaria in Developing and Under Developed Countries

      2. 4.2.2 Awareness Initiatives Undertaken by the Governments

      3. 4.2.3 Increasing Research for New Drugs and New Combinations Therapies

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects Associated with Artemisinin Combination Therapy (ACT) Coupled with Less Availability of Raw Material for Production of ACTs

      2. 4.3.2 Presence of Counterfeit Drugs and Substitutes for ACT

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Combination Therapy Type

      1. 5.1.1 Artemether-Lumefantrine

      2. 5.1.2 Artesunate-Amodiaquine

      3. 5.1.3 Artesunate-Pyronaridine

      4. 5.1.4 Artesunate-Sulfadoxine-Pyrimethamine

      5. 5.1.5 Others

    2. 5.2 Geography

      1. 5.2.1 Asia-Pacific

        1. 5.2.1.1 India

        2. 5.2.1.2 Pakistan

        3. 5.2.1.3 Vietnam

        4. 5.2.1.4 Indonesia

        5. 5.2.1.5 Myanmar

        6. 5.2.1.6 Cambodia

        7. 5.2.1.7 Rest of Asia-Pacific

      2. 5.2.2 South America

        1. 5.2.2.1 Venezuela

        2. 5.2.2.2 Brazil

        3. 5.2.2.3 Colombia

        4. 5.2.2.4 Rest Of South America

      3. 5.2.3 Middle-East and Africa

        1. 5.2.3.1 GCC

        2. 5.2.3.2 South Africa

        3. 5.2.3.3 Nigeria

        4. 5.2.3.4 Uganda

        5. 5.2.3.5 Kenya

        6. 5.2.3.6 Zimbabwe

        7. 5.2.3.7 Niger

        8. 5.2.3.8 Cameroon

        9. 5.2.3.9 Ghana

        10. 5.2.3.10 Democratic Republic of the Congo

        11. 5.2.3.11 Rest of Middle East and Africa

      4. 5.2.4 Rest of the World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Cipla Ltd.

      2. 6.1.2 Desano Inc.

      3. 6.1.3 Hovid Berhad

      4. 6.1.4 KPC Pharmaceuticals

      5. 6.1.5 Guilin Pharmaceutical(Fosun Pharmaceutical )

      6. 6.1.6 Novartis AG

      7. 6.1.7 Sanofi S.A.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Artemisinin Combination Therapy Market market is studied from 2018 - 2026.

The Artemisinin Combination Therapy Market is growing at a CAGR of 8.31% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

Middle-East and Africa holds highest share in 2020.

Fosun Pharmaceutical (Guilin Pharmaceutical), Sanofi S.A., Novartis AG, KPC Pharmaceuticals, Cipla Ltd. are the major companies operating in Artemisinin Combination Therapy Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!